Semaglutide May Reverse Damage Caused by Osteoarthritis, Study Suggests : ScienceAlert

For years, anyone living with sore, creaking knees has tended to hear the same advice: try to lose weight, rely on painkillers, and keep your fingers crossed the joint does not deteriorate further.

A small but eye-catching piece of research now points to a different possibility: a widely used diabetes and weight-loss medicine may do more than ease osteoarthritis symptoms - it may help repair joint damage itself.

Semaglutide and osteoarthritis: moving beyond the weight-loss spotlight

Semaglutide - the active ingredient in Ozempic and Wegovy - has quickly become well known for blood glucose control and substantial weight loss. A research team spanning China and the United States has now investigated semaglutide in a completely different context: osteoarthritis, the world’s most common type of arthritis.

Osteoarthritis develops as the smooth cartilage that cushions joints slowly wears away. As the protective layer thins, bones begin to rub together, leading to pain, stiffness, swelling, and sometimes bone spurs (bony outgrowths). Most available treatments aim to reduce pain and inflammation; they do not reliably rebuild cartilage or halt the condition.

In mouse experiments and a small trial in people, semaglutide seemed to shield - and in part restore - injured joint tissue, in a way that did not depend on weight loss.

That “not due to weight loss” detail matters. If confirmed, it would suggest the drug can act directly on the biology inside the joint, rather than simply reducing load on the knees by making a person lighter.

How semaglutide may protect joint tissue

Semaglutide sits within a group of medicines that mimic GLP‑1, a hormone released after eating. GLP‑1 prompts the pancreas to release insulin and signals to the brain that you feel full. Together, those effects support blood sugar control and reduce appetite, which commonly results in weight loss.

The new work suggests GLP‑1 signalling may also influence processes inside joint tissue more profoundly than previously appreciated.

Reprogramming chondrocytes to generate energy more efficiently

Cartilage is looked after by specialised cells called chondrocytes. In osteoarthritis, chondrocytes become strained and metabolically inefficient. When they cannot keep up with repair demands, cartilage maintenance falters and damage can accelerate.

In mice with both obesity and osteoarthritis, the researchers reported that semaglutide changed the way chondrocytes produce energy. Prior to treatment, these cells primarily depended on glycolysis - a fast, low-efficiency method of extracting energy from glucose without oxygen.

Part-way through the article, a set of unrelated, headline-style links appeared (seemingly inserted as promoted content), including:

• “Hairstyles after 60: Goodbye French bob, the ‘Riviera bob’ is the most… Summer’s rejuvenating hairstyle”
• “Hair dye addiction is quietly ruining scalps everywhere but stylists still say it is safe - how often is too often”
• “Stéphane Macquaire, professional hairdresser in Paris: ‘This is the secret to spacing out appointments between highlights’”
• “With these 3 patents, France grabs the reins of ‘tomorrow’s’ €57 billion energy bet: e‑methanol”
• “‘Your garden uses too much water because it was badly designed’ sustainable landscaping solutions that reduce watering without sacrificing aesthetics”
• “‘No more flat hair after 50’: hairdressers are adamant, here’s the best bob for fine hair”
• “France moves to lock in Europe’s supply of a crucial battery material cars won’t work without in 10 years”
• “India’s biggest rival turns recent clash into showroom for its ‘low-cost’ fighter jet courting 13 countries”

Despite that interruption, the scientific finding reported immediately afterwards was this:

Following semaglutide treatment, chondrocytes moved towards oxidative phosphorylation, an oxygen-dependent pathway that can produce roughly 18 times more energy per glucose molecule.

This shift is important because more available energy can help cells cope under stress and carry out repair and maintenance. The researchers attributed the change to a metabolic signalling chain they describe as the GLP‑1R–AMPK–PFKFB3 axis, which functions like a sequence of molecular switches controlling how the cell uses fuel.

Mouse studies: less cartilage breakdown and fewer bone spurs

In mouse models designed to mimic obesity-associated osteoarthritis, semaglutide was linked with:

• Reduced pain-related behaviour
• Decreased cartilage degradation
• Fewer bone spurs around the joint
• Less severe damage in the synovium (the thin membrane lining the joint)

When researchers compared cartilage from treated versus untreated mice, they observed shifts in the abundance of almost 8,300 proteins - a scale consistent with extensive reworking of cellular activity.

To test whether these benefits were simply due to eating less and losing weight, the scientists also used a pair-fed control group: these mice were given the same amount of food as the semaglutide group and lost a similar amount of weight.

The pair-fed mice did not show the same cartilage protection, which supports the idea that semaglutide directly affected joint cells, rather than acting only through weight reduction.

A small human trial suggests possible benefit in knees

Findings in mice can be compelling, but the key question is whether the effect carries over to humans. To explore that, the team conducted a 24‑week randomised trial involving 20 people aged 50 to 75 who had both obesity and knee osteoarthritis.

Participants were assigned to one of two approaches:

Treatment group	What they received	Main outcomes after 24 weeks
HA only	Sodium hyaluronate (hyaluronic acid injected into the knee)	Pain reduction and improved lubrication, as expected
HA + semaglutide	Sodium hyaluronate plus semaglutide	Lower pain scores, improved knee function, and MRI indications of thicker cartilage and new cartilage growth

Hyaluronic acid injections are already used for some people to improve joint lubrication and relieve pain. In this study, adding semaglutide was associated with noticeably better pain and movement outcomes. Importantly, MRI scans indicated cartilage thickening in weight-bearing parts of the knee - suggesting a structural change rather than symptom control alone.

In the combined-treatment group, cartilage appeared not only preserved but partly regrown in areas that absorb everyday impact.

The study’s size and duration are limitations, so the results are not definitive. Even so, it stands out as one of the first controlled indications that a GLP‑1 medicine might influence the trajectory of osteoarthritis in people, rather than merely dulling symptoms.

Why osteoarthritis needs better treatments urgently

Osteoarthritis is estimated to affect around 600 million people worldwide, with projections rising towards one billion by 2050. Ageing populations, higher obesity rates, and the fact that more people remain physically active later in life are all contributing.

It is not solely a condition of older age. Younger and middle-aged people can also develop osteoarthritis, particularly after joint injuries, through impact sports, or alongside metabolic disorders - potentially leading to many years of pain, stiffness, and reduced activity.

Typical management usually includes:

• Pain relief using tablets or topical gels
• Exercise programmes and physiotherapy
• Weight management
• Occasional steroid injections or hyaluronic acid injections
• Joint replacement surgery once damage becomes severe

Most of these options improve comfort and function without restoring cartilage. A medicine that directly protects or rebuilds joint tissue would represent a meaningful change in osteoarthritis care.

Potential advantages - and important cautions

These findings add to a growing set of reports suggesting GLP‑1 drugs may have “off-label” benefits beyond appetite and blood sugar. Early signals have been discussed for heart disease, fatty liver disease and kidney health - and osteoarthritis may now belong on that list.

However, caution is warranted. Mouse findings do not always predict long-term human outcomes. Here, the human data came from just 20 participants (all with both obesity and osteoarthritis) followed for under six months.

The researchers emphasise that the knee-protective signals seen in people must be interpreted carefully and confirmed in larger, longer clinical trials.

Semaglutide also carries known risks. Common side effects include nausea, vomiting, diarrhoea, and abdominal pain. There are continuing discussions about uncommon but serious concerns such as pancreatitis, gallbladder problems, and how the medicine may interact with other long-term treatments. Using semaglutide solely for joint health would therefore require a careful risk–benefit evaluation.

An additional practical consideration is access and prioritisation. In the UK, semaglutide’s availability depends on indication and local commissioning decisions, and demand has at times outpaced supply. If future trials support semaglutide for osteoarthritis, health services would still need clear guidance on who benefits most (for example, people with obesity-related knee osteoarthritis versus those with osteoarthritis at a healthy weight).

It is also unlikely that any medicine would replace foundational care. Even if cartilage protection is confirmed, strengthening exercises, weight management where appropriate, and physiotherapy-based strategies would still matter for reducing joint load, improving stability, and maintaining mobility.

What this might mean for people with knee pain

If larger trials confirm these early signals, semaglutide - or related GLP‑1 medicines - could eventually sit alongside physiotherapy, injections, and weight-loss support. For someone with obesity and painful knee osteoarthritis, one medicine could potentially address metabolic risk while also helping protect joint structure.

A plausible future example would be a 62-year-old with type 2 diabetes, obesity and knee osteoarthritis who starts semaglutide under specialist oversight. Over months, they lose some weight and their blood glucose improves - but their knee pain and function improve more than expected. Imaging suggests the joint is not worsening as quickly, and cartilage quality appears better. Even modest changes like this could delay, or in some cases avoid, knee replacement surgery.

Scientifically, the study also redirects attention to energy production inside joint cells. If targeting the GLP‑1R–AMPK–PFKFB3 axis makes chondrocytes more robust, future treatments might be designed to act on that pathway more specifically - potentially offering joint benefits with fewer whole-body effects than semaglutide.

Key terms explained

A few definitions make the biology easier to follow:

• Chondrocytes: the primary cells in cartilage. They build and maintain collagen and other structural proteins that create a smooth, shock-absorbing joint surface.
• Glycolysis: a rapid way to produce energy from glucose without using oxygen. Helpful in short bursts, but it yields relatively little energy per molecule.
• Oxidative phosphorylation (OXPHOS): an oxygen-dependent energy pathway in mitochondria. It produces much more energy and supports longer-term cellular function.
• AMPK: the cell’s “fuel gauge”, which detects low energy and adjusts metabolism to restore balance.

By nudging chondrocytes away from the low-yield, stress-style approach of glycolysis and towards OXPHOS, semaglutide may provide enough energy for these cells to survive and maintain cartilage even in the hostile environment of an osteoarthritic joint.

The research, published in Cell Metabolism, does not mean semaglutide is ready to be used as standard osteoarthritis treatment. It does, however, hint that the discussion around joint disease may be shifting - from “wear and tear” alone towards deeper, potentially treatable biology within the joint itself.